Astellas Steps Tentatively Into Global Vaccines, Following Path Of Japanese Competitors
This article was originally published in PharmAsia News
Astellas Pharma Inc. is making forays into the vaccines segment, with the support of development firm ClearPath Development Company to accelerate the process.
You may also be interested in...
Vaccine-focused biotech Vical Inc. announced July 14 that it has inked a global licensing agreement with Japan's Astellas Pharma Inc. to develop and commercialize the biotech's cytomegalovirus (CMV) vaccine, TransVax
As Wall Street fails to significantly reward companies with strong clinical news, the fall-out also affects the project financiers, like Symphony Capital -- an increasingly important alternative to traditional equity or alliance financing. On one hand, the hard times make Symphony's expensive-looking capital increasingly attractive to biotechs, including companies that once would have had plenty of other financing alternatives. On the other, Symphony's model is shifting more toward equity investing. It's still financing projects, but it's padding its upside with a lot more cheap stock.
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?